General Fusion Inc. develops commercial Magnetized Target Fusion, a hybrid between magnetic fusion and inertial confinement fusion for transforming energy supply. It also develops scale subsystems, including scale plasma injectors, acoustic drivers, and liquid metal vortex compression tests. The company was founded in 2002 and is based in Burnaby, Canada.
Realeyes Data Services Ltd., an emotions research company, provides web-based facial expression measurement solutions for video advertisements. The company’s solutions enable users to read how people feel about their video advertisements using computer vision. It offers Tentpole Creative, Digital Content, Live Interaction, consumer insight, and creative performance. The company was founded in 2007 and is headquartered in London, United Kingdom with additional offices in New York, New York; Tokyo, Japan; and Budapest, Hungary.
OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal "Bi-Directional Delivery" which allows drugs to be more efficiently delivered to the nasal cavity. By applying its drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices. The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown that devices can provide a faster onset of action, greater effect with a lower dose, and reduced side effects. The company has offices in Norway and the UK.
Vasopharm GmbH is a biopharmaceutical company based in Würzburg, Germany, that focuses on discovering and developing innovative therapeutics for cerebro- and cardiovascular diseases. Established in 1998, the company targets acute niche indications with significant unmet medical needs, emphasizing clinical efficacy in its drug development efforts. Vasopharm's therapeutic pipeline includes VAS203, an allosteric nitric oxide synthase inhibitor designed to reduce excessive nitric oxide production in cerebral vessels, thereby preventing dangerous increases in intracranial pressure after traumatic brain injury. Another key candidate, VAS2870, is a modulator of NAD(P)H oxidase, aimed at treating peripheral arterial occlusive diseases. Through its research, Vasopharm aims to influence the bioavailability of nitric oxide, a critical cellular signaling molecule involved in various physiological and pathological processes.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
General Fusion Inc. develops commercial Magnetized Target Fusion, a hybrid between magnetic fusion and inertial confinement fusion for transforming energy supply. It also develops scale subsystems, including scale plasma injectors, acoustic drivers, and liquid metal vortex compression tests. The company was founded in 2002 and is based in Burnaby, Canada.
D3O Lab Limited provides impact protection and shock absorption solutions. It offers head, limb, back, and hand protectors; knee pads; footwear solutions; smart skin products; and sheet materials in sport, electronics, footwear, motorcycle, defense and law enforcement protection, and industrial and medical markets. The company was founded in 2001 and is based in London, United Kingdom.
Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.
Fit Origin is the ultimate fit recommendation solution for eCommerce fashion retailers which puts fit and body shapes at the heart of the online shopping experience. It combines garment data and shopper data to determine which size garment will fit them, the way they want to wear it. Each shopper’s measurements are calculated based on height, weight, age and body shape. Deep statistical analysis of thousands of detailed body scans allows their data scientists to use these limited data points to infer high quality information about the shopper’s measurements. Every garment is analysed by their garment technologists, taking many factors into account including silhouette, stretch and fit preference. A shopper’s body measurements are used in conjunction with garment measurements to interpret how each size will fit a shopper. Fit Origin recommends the best size to fit shoppers, with the ability to compare sizes based on their own fit preferences. Their fit recommendation solution allows your shoppers to buy with confidence. At Rakuten Fits Me they are all about ‘Me’ fashion, not mass fashion. They are the only size and fit solution provider to align your product data with shopper body data so they get the perfect fit, first time, every time.
SmartKem Limited is a company based in Manchester, United Kingdom, that specializes in the development and marketing of organic semiconductors aimed at enhancing liquid crystal and organic light-emitting diode displays. Founded in 2008, SmartKem focuses on the design and industrialization of low-temperature, solution-deposited organic semiconductors, particularly for transistor backplanes. The company's flagship product, truFLEX, is part of a technology platform designed to create high-performance, lightweight, and cost-effective electronic circuits on polymer films. Operating from the Optic Technium center in North Wales, SmartKem aims to meet the growing demand for affordable and energy-efficient electronics. The company is recognized for its expertise in organic semiconductors, printing technology, and electronic device construction, having recently won the Oxford Venturefest gold award for British Technology Innovation of the Year.
OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal "Bi-Directional Delivery" which allows drugs to be more efficiently delivered to the nasal cavity. By applying its drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices. The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown that devices can provide a faster onset of action, greater effect with a lower dose, and reduced side effects. The company has offices in Norway and the UK.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
Xeros Ltd. is a new company focused on the development of "virtually waterless" laundry cleaning. Harnessing over 30 years of research by Professor Stephen Burkinshaw and the University of Leeds, Xeros is the brand name for a patented polymer based cleaning that creates step change advantage in the cost and environmental impact of aqueous wash cleaning.
General Fusion Inc. develops commercial Magnetized Target Fusion, a hybrid between magnetic fusion and inertial confinement fusion for transforming energy supply. It also develops scale subsystems, including scale plasma injectors, acoustic drivers, and liquid metal vortex compression tests. The company was founded in 2002 and is based in Burnaby, Canada.
Vasopharm GmbH is a biopharmaceutical company based in Würzburg, Germany, that focuses on discovering and developing innovative therapeutics for cerebro- and cardiovascular diseases. Established in 1998, the company targets acute niche indications with significant unmet medical needs, emphasizing clinical efficacy in its drug development efforts. Vasopharm's therapeutic pipeline includes VAS203, an allosteric nitric oxide synthase inhibitor designed to reduce excessive nitric oxide production in cerebral vessels, thereby preventing dangerous increases in intracranial pressure after traumatic brain injury. Another key candidate, VAS2870, is a modulator of NAD(P)H oxidase, aimed at treating peripheral arterial occlusive diseases. Through its research, Vasopharm aims to influence the bioavailability of nitric oxide, a critical cellular signaling molecule involved in various physiological and pathological processes.
NewMotion specializes in providing advanced charging solutions for electric vehicle (EV) drivers and charging locations. The company focuses on enabling EV users to maximize their electric driving experience by utilizing renewable energy sources for charging. With a network comprising over 12,000 connected charge points, NewMotion boasts one of the largest and most frequently used charging networks in Europe. In the Netherlands, two out of three electric vehicle drivers utilize NewMotion's charging solutions. The company caters to both individual and commercial clients, offering charging stations and solutions for businesses while collaborating with leasing companies and car manufacturers. NewMotion is actively expanding its operations across the Netherlands, Belgium, Germany, and Norway.
Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.
Fit Origin is the ultimate fit recommendation solution for eCommerce fashion retailers which puts fit and body shapes at the heart of the online shopping experience. It combines garment data and shopper data to determine which size garment will fit them, the way they want to wear it. Each shopper’s measurements are calculated based on height, weight, age and body shape. Deep statistical analysis of thousands of detailed body scans allows their data scientists to use these limited data points to infer high quality information about the shopper’s measurements. Every garment is analysed by their garment technologists, taking many factors into account including silhouette, stretch and fit preference. A shopper’s body measurements are used in conjunction with garment measurements to interpret how each size will fit a shopper. Fit Origin recommends the best size to fit shoppers, with the ability to compare sizes based on their own fit preferences. Their fit recommendation solution allows your shoppers to buy with confidence. At Rakuten Fits Me they are all about ‘Me’ fashion, not mass fashion. They are the only size and fit solution provider to align your product data with shopper body data so they get the perfect fit, first time, every time.
Xeros Ltd. is a new company focused on the development of "virtually waterless" laundry cleaning. Harnessing over 30 years of research by Professor Stephen Burkinshaw and the University of Leeds, Xeros is the brand name for a patented polymer based cleaning that creates step change advantage in the cost and environmental impact of aqueous wash cleaning.
Realeyes Data Services Ltd., an emotions research company, provides web-based facial expression measurement solutions for video advertisements. The company’s solutions enable users to read how people feel about their video advertisements using computer vision. It offers Tentpole Creative, Digital Content, Live Interaction, consumer insight, and creative performance. The company was founded in 2007 and is headquartered in London, United Kingdom with additional offices in New York, New York; Tokyo, Japan; and Budapest, Hungary.
Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.
Prosonix Ltd. operates as a specialty pharmaceutical company, which develops and markets a portfolio of inhaled respiratory medicines to treat asthma and chronic obstructive pulmonary diseases. It develops generic mono and combination therapies based on inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA); and dual and triple combination therapies for respiratory diseases based on its multiple-component particle technology. The company was founded in 2006 and is based in Oxford, United Kingdom. As of June 15, 2015, Prosonix Ltd. operates as a subsidiary of Circassia Limited.
NewMotion specializes in providing advanced charging solutions for electric vehicle (EV) drivers and charging locations. The company focuses on enabling EV users to maximize their electric driving experience by utilizing renewable energy sources for charging. With a network comprising over 12,000 connected charge points, NewMotion boasts one of the largest and most frequently used charging networks in Europe. In the Netherlands, two out of three electric vehicle drivers utilize NewMotion's charging solutions. The company caters to both individual and commercial clients, offering charging stations and solutions for businesses while collaborating with leasing companies and car manufacturers. NewMotion is actively expanding its operations across the Netherlands, Belgium, Germany, and Norway.
Soasta, Inc. is a digital performance management company based in Mountain View, California, specializing in cloud testing, performance testing, real user monitoring, and application testing for web and mobile environments. Established in 2006, the company offers a suite of products, including mPulse for real user monitoring, CloudTest for load and performance testing, TouchTest for mobile functional testing, and a Digital Operations Center for performance visibility. Soasta's platform enables businesses to gain real-time insights into user experiences, allowing them to optimize performance and align it with business objectives. The company has conducted over 10 million tests and measured more than 100 billion user experiences, serving a diverse clientele that includes notable names in various industries. Additionally, Soasta provides comprehensive support services, including strategic assessments, test planning, execution, and training options for clients. As of 2017, Soasta operates as a subsidiary of Akamai Technologies.
CYTOO focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening.
They develop, manufacture, and distribute products that make cellular analysis robust and reliable by dramatically decreasing cell variability.
There new micropattern-based products are designed to meet the needs of all clients whatever their research goals. They are open to suggestions or specific requests that can improve and spread the scope of this breakthrough in quantitative cell analysis.
Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.
Prosonix Ltd. operates as a specialty pharmaceutical company, which develops and markets a portfolio of inhaled respiratory medicines to treat asthma and chronic obstructive pulmonary diseases. It develops generic mono and combination therapies based on inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA); and dual and triple combination therapies for respiratory diseases based on its multiple-component particle technology. The company was founded in 2006 and is based in Oxford, United Kingdom. As of June 15, 2015, Prosonix Ltd. operates as a subsidiary of Circassia Limited.
General Fusion Inc. develops commercial Magnetized Target Fusion, a hybrid between magnetic fusion and inertial confinement fusion for transforming energy supply. It also develops scale subsystems, including scale plasma injectors, acoustic drivers, and liquid metal vortex compression tests. The company was founded in 2002 and is based in Burnaby, Canada.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
Accept Software
Series C in 2010
Accept helps companies increase the speed and certainty of new product success and turn product innovation into a competitive advantage. Accept SaaS innovation management solutions help companies engage communities, prioritize and manage new ideas, align products with company strategy, and unify execution across teams.
Xeros Ltd. is a new company focused on the development of "virtually waterless" laundry cleaning. Harnessing over 30 years of research by Professor Stephen Burkinshaw and the University of Leeds, Xeros is the brand name for a patented polymer based cleaning that creates step change advantage in the cost and environmental impact of aqueous wash cleaning.
Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.
Evolva Holding SA is a biotechnology company based in Switzerland that specializes in discovering, developing, and commercializing innovative ingredients for various sectors, including food, nutrition, personal healthcare, and agriculture. Founded in 2004, the company leverages a proprietary synthetic biology technology platform to create high-quality ingredients that mirror the properties of natural products while eliminating their drawbacks. Evolva's product portfolio includes branded ingredients like Veri-te Resveratrol, used for age-related health, and EverSweet Stevia, a natural sweetener. Additionally, the company offers Nootkashield for pest control, EveNootkatone for flavor and fragrance applications, and EveValencene, a citrus flavoring. Evolva serves diverse markets, including nutrition, flavors and fragrances, animal health, personal care, and pharmaceuticals, both developing its own products and collaborating with other industry players.
General Fusion Inc. develops commercial Magnetized Target Fusion, a hybrid between magnetic fusion and inertial confinement fusion for transforming energy supply. It also develops scale subsystems, including scale plasma injectors, acoustic drivers, and liquid metal vortex compression tests. The company was founded in 2002 and is based in Burnaby, Canada.
Inge Watertechnologies specializes in ultrafiltration technology aimed at enhancing water treatment processes for various applications, including drinking water, seawater, wastewater, and processed water. The company employs a membrane separation process that utilizes high-tech membranes with ultra-small pore filters. This advanced technology effectively captures particles, suspended solids, and microorganisms, including bacteria and viruses, ensuring a reliable supply of clean water. Inge's solutions are designed to promote smart and safe water treatment, addressing the growing demand for dependable water sources across different sectors.
Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.
VAIREX international limitedis a privately held designer, manufacturer, and supplier of air management systems. These critical and efficient systems, consisting of integrated compressors, motors, and controllers, deliver clean air in hydrogen fuel cell and diesel emissions control devices.
VAIREX's customers include leading Tier One suppliers and OEMs to the fuel cell and diesel industries in Europe, Asia, and North America.
Exosect Limited, established in 2001 as a spin-out from the University of Southampton, specializes in developing innovative platforms that enhance the delivery of biological and synthetic active ingredients for pesticide manufacturers. The company's proprietary technologies, including the Entostat and Entomag delivery platforms, address challenges such as pest resistance, regulatory compliance, and food safety residues. The Entostat platform utilizes an electrostatically charged micro powder for microencapsulation and controlled release of active ingredients, while the Entomag platform employs ferrous micro powder for targeted delivery, particularly against crawling insects in public health applications. With a robust portfolio of 41 patents and 28 national product registrations, Exosect is strategically positioned to commercialize its patented technologies across agriculture, public health, and animal health sectors, aiming to improve pest control and food protection. The company is headquartered in Winchester, United Kingdom.
iPolicy Networks is the developer of the world's first Intrusion Prevention Firewall delivering real-time, consistent security enforcement for enterprises, carriers and managed security service providers. The iPolicy Intrusion Prevention Firewall supports multiple security functions built on iPolicy's Single Pass Architecture(TM) that enables superior performance even under heavy traffic load.
t2cure GmbH, a biopharmaceutical company, develops progenitor cell-based regenerative therapeutics. It provides autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular diseases, including ischemic heart diseases, such as acute myocardial infarction and chronic ischemic heart diseases, non-ischemic heart failure, peripheral arterial occlusive disease, and diabetic polyneuropathy. The company was founded in 2006 and is based in Frankfurt am Main, Germany.
iPolicy Networks is the developer of the world's first Intrusion Prevention Firewall delivering real-time, consistent security enforcement for enterprises, carriers and managed security service providers. The iPolicy Intrusion Prevention Firewall supports multiple security functions built on iPolicy's Single Pass Architecture(TM) that enables superior performance even under heavy traffic load.
Founded in 1999, Mblox are the original SMS company. With over 100 direct carrier relationships and a global reputation for expertise in mobile messaging, they are trusted by more companies to carry their mission-critical traffic than any other service. Their cloud based mobile messaging platform processes 7 billion mobile messages a year on behalf of more than 4,000 customers. They provide services to fit any size business, from the small start-up to the largest multinational organisation. Every customer has access to 24/7 email support as standard, provided by an in-house team of experts. In addition they offer a variety of support packages to meet your business needs.